General Information of Drug Combination (ID: DCNN8TM)

Drug Combination Name
Indazole derivative 5 Arfolitixorin
Indication
Disease Entry Status REF
Renal cell carcinoma Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R Arfolitixorin   DMIXMYK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SN12C
Zero Interaction Potency (ZIP) Score: 0.04
Bliss Independence Score: 4.07
Loewe Additivity Score: 4.13
LHighest Single Agent (HSA) Score: 5.37

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Arfolitixorin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCQZN8Y MOLT-4 Investigative [1]
Astrocytoma DC4TXOY SNB-19 Investigative [1]
Clear cell renal cell carcinoma DC6ATLE 786-0 Investigative [1]
Glioblastoma DCA4SHD SNB-75 Investigative [1]
Breast adenocarcinoma DCUDBPP MDA-MB-468 Investigative [4]
Carcinoma DCBPQE0 RXF 393 Investigative [4]
Carcinoma DCYLNE3 MCF7 Investigative [4]
Adenocarcinoma DCLFUE5 DU-145 Investigative [5]
High grade ovarian serous adenocarcinoma DCSP1YC OVCAR-8 Investigative [5]
High grade ovarian serous adenocarcinoma DCT9LBC NCI\\/ADR-RES Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
5 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976